A window on reality?

Journal of Clinical Oncology

Volumn 22, Issue 8, 2004, Pages 1360-1362

  Smith, Malcolm A ^a   Anderson, Barry D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG MECHANISM; DRUG TOLERABILITY; EDITORIAL; EWING SARCOMA; GLIOMA; HUMAN; NEUROBLASTOMA; ONCOLOGY; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; XENOGRAFT; MEDICAL ETHICS; NOTE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; ETHICS, MEDICAL; HUMANS; RHABDOMYOSARCOMA; TOPOTECAN; TREATMENT OUTCOME;

EID: 2342627977     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.01.946     Document Type: Editorial

References (11)

1. Walterhouse DO, Lyden ER, Breitfeld PP, et al: Efficacy of topotecan and cyclophosphamide given as a phase II window in children with newly diagnosed metastatic rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 22:1398-1403, 2004
2. Tubergen DG, Stewart CF, Pratt CB, et al: Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A pediatric oncology group study. J Pediatr Hematol Oncol 18:352-361, 1996
3. Houghton PJ, Cheshire PJ, Myers L, et al: Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 31:229-239, 1992
4. Nitschke R, Parkhurst J, Sullivan J, et al: Topotecan in pediatric patients with recurrent and progressive solid tumors: A Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 20:315-318, 1998
5. Bomgaars L, Berg SL, Blaney SM: The development of camptothecin analogs in childhood cancers. Oncologist 6:506-516, 2001
6. Rodriguez-Galindo C, Radomski K, Stewart CF, et al: Clinical use of topoisomerase I inhibitors in anticancer treatment. Med Pediatr Oncol 35:385-402, 2000
7. Rowinsky EK, Kaufmann SH: Topotecan in combination chemotherapy. Semin Oncol 24:S20, 1997 (6 suppl 20)
8. Saylors RL III, Stewart CF, Zamboni WC, et al: Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: A Pediatric Oncology Group Study. J Clin Oncol 16:945-952, 1998
9. Saylors RL III, Stine KC, Sullivan J, et al: Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol 19:3463-3469, 2001
10. Sandler E, Lyden E, Ruymann F, et al: Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol 37:442-448, 2001
11. Smith MA, Anderson B: Phase II window studies: 10 years of experience and counting. J Pediatr Hematol Oncol 23:334-337, 2001